The latest shared research on Oncology
Big Pharma + Big Pharma = Collaborative Approach to Fight Cancer
Shannon Fisher, Citeline Senior Manager, Oncology and Analytics Targeted medicines are hot. It is no surprise that they are now “getting married”. These couples are being created by top tier pharmaceutical companies partnering with each other for the combined development of their individual targeted drugs, offering a double-team approach to fighting cancer. This approach to drug development is different than the standard approach of “Big Pharma” in-licensing a promising drug or technology from a smaller company and developing it on their own or in conjunction with that company. In this new experimental tactic, development is occurring on two individual drugs, each drug ...
Analysis of clinical trial results presented at ASH 2011
The 53rd Annual American Society of Hematology Meeting and Exposition (ASH 2011) was held on December 10-13 in San Diego, CA. In this report, Citeline Analytics provides an overview of the clinical trials reported at ASH 2011 that are included in Citeline’s Trialtrove portfolio. The analysis focuses on the trial phases, leading companies, diseases, types of results reported and key drugs studied. Highlights: The vast majority of trials reported were in hematological cancers, with multiple myeloma and non-Hodgkin’s lymphoma predominating 80% of the phase I clinical trials presented were sponsored by the industry Pipeline drugs were studied in 23% of the industry sponsored trials reported Celgene ...
Innovations in the Delivery of Cancer Therapies: Technological advances, Growth Opportunities and Future Market Outlook
During the last five years the industry has signed more than 440 agreements with drug delivery specialists, of these, approximately 10% focused on the delivery of anti-cancer or cancer-related drugs. The strategic alliances which have been established span a range of delivery technologies, drug classes and companies. Whilst many deals have focused on advanced parenteral delivery others have begun to focus on the oral delivery of injectable anticancer agents. Another area of intense research is the development of drugs to treat “hard-to-treat” cancers such as glioblastomas and the development of RNAi-based therapeutics which have caused a surge of activity as companies ...
Knockdown of β-Catenin Through shRNA Cause a Reversal of EMT and Metastatic Phenotypes Induced by HIF-1α
Abstract from: Knockdown of β-Catenin Through shRNA Cause a Reversal of EMT and Metastatic Phenotypes Induced by HIF-1α, Jia-Hui Zhao, Yong Luo, Yong-Guang Jiang, Da-Lin He, Chun-Ting Wu, Cancer Investigation Jun 2011, Vol. 29, No. 6, Pages 377-382: 377-382. Objective Wnt/β-catenin signaling pathway regulates pattern formation during embryogenesis as well as tumor progression. Numbers of studies suggest that this signaling pathway may play an important role in Epithelial-Mesenchymal transition (EMT), however, there was no evidence that Wnt/β-catenin signaling pathway directly controlled the EMT occurrence. Our previous research has successfully proved that overexpression of hypoxia inducible factor-1α (HIF-1α) could induce EMT in LNCaP ...
Tesaro’s $101 Million Series B to Fund Rolapitant Ph III and Build Oncology Portfolio
Sukaina Virji sukaina.virji@informa.com In what is the largest strictly venture-funded financing of the year so far, Tesaro - an oncology-focused biotech company - has raised $101 million in a series B round. Kleiner Perkins Caufield & Byers led the round with participants including founding investor New Enterprise Associates (NEA) and new investors InterWest Partners, T Rowe Price, Pappas Ventures, Oracle Partners, Deerfield Management and Leerink Swann. Boston-based Tesaro was co-founded by former executives of MGI Pharma, an oncology and acute-care focused biotech that was acquired by Eisai in 2008 for $3.9 billion. NEA and Tesaro management funded an initial $20 million series A ...
Updated Evidence in Support of Diet and Exercise Interventions in Cancer Survivors
Abstract from: Updated evidence in support of diet and exercise interventions in cancer survivors, Dorothy W. Pekmezi, Wendy Demark-Wahnefried, Acta Oncologica Feb 2011, Vol. 50, No. 2, Pages 167-178: 167-178. Background A growing body of evidence suggests that diet and exercise behaviors and body weight status influence health-related outcomes after a cancer diagnosis. This review synthesizes the recent progress in lifestyle interventions in light of current guidelines put forth by the American Cancer Society (ACS), the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) and the American College of Sports Medicine (ACSM). Methods The PubMed database was searched for terms of cancer survivor(s) ...
Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Abstract from: Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer, Susanna V. Ulahannan, Julie R. Brahmer, Cancer Investigation Apr 2011, Vol. 29, No. 4, Pages 325-337: 325-337. Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC. Several multitargeted antiangiogenic tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, cediranib, vandetanib, BIBF 1120, pazopanib, and axitinib) are also being evaluated in combination with standard chemotherapy. Here we review current ...
Late Effects of Breast Cancer Treatment and Potentials for Rehabilitation
Abstract from: Late effects of breast cancer treatment and potentials for rehabilitation, Marianne Ewertz, Anders Bonde Jensen, Acta Oncologica Feb 2011, Vol. 50, No. 2, Pages 187-193: 187-193. Background Breast cancer is the most frequent malignant disease among women world wide. Survival has been improving leading to an increasing number of breast cancer survivors, in the US estimated to about 2.6 million. Material and methods The literature was reviewed with focus on data from the Nordic countries. Results Local therapies such as breast cancer surgery and radiotherapy may cause persistent pain in the breast area, arm, and shoulder reported by 30–50% of patients after three to ...
Evotec and Roche Team Up to Develop Oncology Biomarkers
Gemma Sharman gemma.sharman@informa.com Evotec and Roche will be collaborating to develop novel biomarkers for Roche's oncology drugs using Evotec's PhosphoScout platform, in what will be the first commercial application of the platform since Evotec inherited it from its acquisition of Kinaxo earlier this year (scripintelligence.com, 15 February). Under the initial three-year term, Evotec will deliver novel protein-activity based biomarkers using the PhosphoScout platform, while Roche will be responsible for conducting clinical trials as well as assessing the development of companion diagnostics for patient stratification. "Kinaxo has already signed similar PhosphoScout deals with Takeda in March 2011 and Daiichi Sankyo in October 2010, but ...
The Number of Drugs in Phase III Development Increased By 13% Representing the Largest Year Over Year Improvement Seen
While the Numbers are Promising the Amount of Innovations Remains Limited Citeline recently completed its comprehensive year on year assessment of the pharmaceutical industry's drug development pipeline. Citeline's 2011 Annual Review of Trends in Pharmaceutical R&D released on June 24 found that the overall size and potential of the pharmaceutical industry, as judged by growth in its drug development pipeline, remained flat, although improvements were seen in certain specific trends, foretelling of possible better times ahead. Ian Lloyd, Editorial Director of Citeline's Drug Information Service, commented that while overall drug development did not grow the number of drugs entering Phase III trials ...
